Hemay007 vs infliximab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

Hemay007

Developed by Tianjin Hemay Pharmaceutical

Phase 1 in Crohn's Diseasesmall molecule
Weak signal

NCT02603185 · Phase 1 · status unknown

This is a randomized, double-blind, placebo-controlled early-phase safety and pharmacokinetics study conducted in healthy volunteers rather than in patients with the target condition, with adverse-event monitoring as its primary endpoint rather than a measure of disease benefit. No results have been posted yet. Its registered primary outcome on ClinicalTrials.gov is "Adverse events assessments after single and multiple ascending dose administration at baseline and repeatedly until study completion". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Crohn's Diseasemonoclonal antibody (chimeric IgG1)
Reliable signal

NCT00094458 · Phase 3 · completed

This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).

Next expected readout: November 2026 · NCT05906576 (registry estimate)

Reported efficacy

Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine) (met)

Result source: NCT00094458

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHemay007infliximab
Clinical remission (induction)—Not reported47.3% vs 34.1%vs Azathioprine + Placebowk 10 · n 169NCT00094458
5 other results
  • 59.8% vs 34.1% wk 10 · n 169 · Phase 3 · secondary NCT00094458
  • 49.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 52.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 32.5% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
  • 36.7% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
Endoscopic response (induction)—Not reported—Not posted · NCT00004941
Clinical remission (maintenance)—Not reported66% vs 54.7%vs Azathioprine + Placebowk 50 · n 97NCT00094458
7 other results
  • 74.1% vs 54.7% wk 50 · n 108 · Phase 3 · secondary NCT00094458
  • 72.2% vs 58.7% wk 42 · n 97 · Phase 3 · secondary NCT00094458
  • 73.1% vs 58.7% wk 42 · n 108 · Phase 3 · secondary NCT00094458
  • 66% vs 61.3% wk 34 · n 97 · Phase 3 · secondary NCT00094458
  • 69.4% vs 61.3% wk 34 · n 108 · Phase 3 · secondary NCT00094458
  • 47.9% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
  • 60.4% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
Endoscopic response (maintenance)—Not reported—Not posted · NCT00004941

Clinical remission (induction)

Hemay007
—Not reported
infliximab
47.3% vs 34.1%vs Azathioprine + Placebowk 10 · n 169NCT00094458
5 other results
  • 59.8% vs 34.1% wk 10 · n 169 · Phase 3 · secondary NCT00094458
  • 49.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 52.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 32.5% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
  • 36.7% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458

Endoscopic response (induction)

Hemay007
—Not reported
infliximab
—Not posted · NCT00004941

Clinical remission (maintenance)

Hemay007
—Not reported
infliximab
66% vs 54.7%vs Azathioprine + Placebowk 50 · n 97NCT00094458
7 other results
  • 74.1% vs 54.7% wk 50 · n 108 · Phase 3 · secondary NCT00094458
  • 72.2% vs 58.7% wk 42 · n 97 · Phase 3 · secondary NCT00094458
  • 73.1% vs 58.7% wk 42 · n 108 · Phase 3 · secondary NCT00094458
  • 66% vs 61.3% wk 34 · n 97 · Phase 3 · secondary NCT00094458
  • 69.4% vs 61.3% wk 34 · n 108 · Phase 3 · secondary NCT00094458
  • 47.9% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
  • 60.4% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458

Endoscopic response (maintenance)

Hemay007
—Not reported
infliximab
—Not posted · NCT00004941
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Hemay007: no structured comparison results are available for Crohn's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Hemay007: 0 of 4 rows · infliximab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinfliximab
Dropout rate
28.4%Infliximab + Azathioprinea
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
34.3%Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
0%
NCT01580670 · Phase 3 · monotherapy
13.3%
NCT00805766 · Phase 3 · monotherapy
18.2%
NCT00688636 · Phase 4 · registry result, not featured evidence
50%
NCT00791557 · Phase na · registry result, not featured evidence
Discontinued due to AEs
16.6%Infliximab + Azathioprinea
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
11.8%Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—
NCT01580670 · Phase 3 · monotherapy
2.2%
NCT00805766 · Phase 3 · monotherapy
18.2%
NCT00688636 · Phase 4 · registry result, not featured evidence
50%
NCT00791557 · Phase na · registry result, not featured evidence
Serious AEs
—Infliximab + Azathioprinea
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
—Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
14%W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
16%W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
1.9%W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
15.5%W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
14.3%
NCT01580670 · Phase 3 · monotherapy
—
NCT00805766 · Phase 3 · monotherapy
9.1%
NCT00688636 · Phase 4 · registry result, not featured evidence
0%
NCT00791557 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
nausea 21.8%
abdominal pain 13.4%
fatigue 13.4%
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 6 more results
abdominal pain 20.9%
nausea 16.6%
arthralgia 14.1%
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
abdominal pain 9.3%
nasopharyngitis 8.3%
crohn's disease 5.6%
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
abdominal pain 11.3%
nausea 11.3%
vomiting 11.3%
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
double stranded dna antibody positive 50%
gastroenteritis 21.4%
headache 21.4%
NCT01580670 · Phase 3 · monotherapy
infusion reaction 18.2% (placebo 7.7%)
abcess 9.1% (placebo 7.7%)
bronchitis 9.1% (placebo 0%)
NCT00688636 · Phase 4 · registry result, not featured evidence
bone marrow suppression 50%
infection 50%
infusion reaction 50%
NCT00791557 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

infliximab

Corticosteroid-free Clinical Remission 44.4% (n=169) vs 30% (n=170) Azathioprine + Placebo @ 26wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
56.8% (n=169) vs 30% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
60.8% (n=97) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
72.2% (n=108) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Mucosal Healing 30.1% (n=93) vs 16.5% (n=109) Azathioprine + Placebo @ 26wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
43.9% (n=107) vs 16.5% (n=109) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Clinical Remission 32.5% (n=169) vs 17.6% (n=170) Azathioprine + Placebo @ 2wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
36.7% (n=169) vs 17.6% (n=170) Azathioprine + Placebo @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
49.1% (n=169) vs 27.6% (n=170) Azathioprine + Placebo @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
52.1% (n=169) vs 27.6% (n=170) Azathioprine + Placebo @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
47.3% (n=169) vs 34.1% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
59.8% (n=169) vs 34.1% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
49.7% (n=169) vs 33.5% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
60.4% (n=169) vs 33.5% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
47.9% (n=169) vs 31.8% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
60.4% (n=169) vs 31.8% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
66% (n=97) vs 61.3% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
69.4% (n=108) vs 61.3% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
72.2% (n=97) vs 58.7% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
73.1% (n=108) vs 58.7% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
66% (n=97) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
74.1% (n=108) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
CDAI 42.6% (n=169) vs 22.4% (n=170) Azathioprine + Placebo @ 2wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
47.3% (n=169) vs 22.4% (n=170) Azathioprine + Placebo @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
54.4% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
63.3% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
55.6% (n=169) vs 39.4% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
69.2% (n=169) vs 39.4% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
55% (n=169) vs 38.8% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
62.7% (n=169) vs 38.8% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
54.4% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
62.1% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
76.3% (n=97) vs 66.7% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
76.9% (n=108) vs 66.7% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
74.2% (n=97) vs 65.3% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
77.8% (n=108) vs 65.3% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
72.2% (n=97) vs 62.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
78.7% (n=108) vs 62.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
IBDQ Total 27.7 vs 20.1 Azathioprine + Placebo score @ 2wk
absolute change · score
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 9 more results
31.4 vs 20.1 Azathioprine + Placebo score @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
34.8 vs 28.3 Azathioprine + Placebo score @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
39.9 vs 28.3 Azathioprine + Placebo score @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
37.8 vs 31 Azathioprine + Placebo score @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
42.4 vs 31 Azathioprine + Placebo score @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
39.9 vs 30.3 Azathioprine + Placebo score @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
43.7 vs 30.3 Azathioprine + Placebo score @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
39.9 vs 31.4 Azathioprine + Placebo score @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
45.2 vs 31.4 Azathioprine + Placebo score @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Average Corticosteroid Use mg Per 21.2 vs 22.92 Azathioprine + Placebo per day @ 2wk
absolute value · per day
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 9 more results
22.75 vs 22.92 Azathioprine + Placebo per day @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
17.68 vs 18.56 Azathioprine + Placebo per day @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
18.26 vs 18.56 Azathioprine + Placebo per day @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
15.68 vs 16.19 Azathioprine + Placebo per day @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
15.01 vs 16.19 Azathioprine + Placebo per day @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
13.23 vs 13.49 Azathioprine + Placebo per day @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
11.64 vs 13.49 Azathioprine + Placebo per day @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
10.96 vs 11.57 Azathioprine + Placebo per day @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
9.35 vs 11.57 Azathioprine + Placebo per day @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
PCDAI 78.6% (n=14) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01580670 · Phase 3 · monotherapy
show 13 more results
100% (n=14) @ 6wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 10wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 14wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 18wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 22wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 26wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 30wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 34wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 38wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 42wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 46wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 50wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 54wk
NCT01580670 · Phase 3 · monotherapy
PCDAI 85.7% (n=14) @ 54wk
responder rate · % of participants
No placebo or comparator arm
The last time point
NCT01580670 · Phase 3 · monotherapy
PCDAI -20.71 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT01580670 · Phase 3 · monotherapy
show 13 more results
-27.68 score @ 6wk
NCT01580670 · Phase 3 · monotherapy
-30 score @ 10wk
NCT01580670 · Phase 3 · monotherapy
-28.57 score @ 14wk
NCT01580670 · Phase 3 · monotherapy
-31.07 score @ 18wk
NCT01580670 · Phase 3 · monotherapy
-27.32 score @ 22wk
NCT01580670 · Phase 3 · monotherapy
-30.18 score @ 26wk
NCT01580670 · Phase 3 · monotherapy
-26.07 score @ 30wk
NCT01580670 · Phase 3 · monotherapy
-30.21 score @ 34wk
NCT01580670 · Phase 3 · monotherapy
-26.25 score @ 38wk
NCT01580670 · Phase 3 · monotherapy
-30.42 score @ 42wk
NCT01580670 · Phase 3 · monotherapy
-27.08 score @ 46wk
NCT01580670 · Phase 3 · monotherapy
-32.5 score @ 50wk
NCT01580670 · Phase 3 · monotherapy
-28.33 score @ 54wk
NCT01580670 · Phase 3 · monotherapy
PCDAI -26.25 score @ 54wk
absolute change · score
No placebo or comparator arm
The last time point
NCT01580670 · Phase 3 · monotherapy
PCDAI Remission 42.9% (n=14) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01580670 · Phase 3 · monotherapy
show 13 more results
78.6% (n=14) @ 6wk
NCT01580670 · Phase 3 · monotherapy
71.4% (n=14) @ 10wk
NCT01580670 · Phase 3 · monotherapy
85.7% (n=14) @ 14wk
NCT01580670 · Phase 3 · monotherapy
85.7% (n=14) @ 18wk
NCT01580670 · Phase 3 · monotherapy
71.4% (n=14) @ 22wk
NCT01580670 · Phase 3 · monotherapy
78.6% (n=14) @ 26wk
NCT01580670 · Phase 3 · monotherapy
64.3% (n=14) @ 30wk
NCT01580670 · Phase 3 · monotherapy
83.3% (n=14) @ 34wk
NCT01580670 · Phase 3 · monotherapy
75% (n=14) @ 38wk
NCT01580670 · Phase 3 · monotherapy
83.3% (n=14) @ 42wk
NCT01580670 · Phase 3 · monotherapy
75% (n=14) @ 46wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 50wk
NCT01580670 · Phase 3 · monotherapy
75% (n=14) @ 54wk
NCT01580670 · Phase 3 · monotherapy
PCDAI Remission 64.3% (n=14) @ 54wk
responder rate · % of participants
No placebo or comparator arm
The last time point
NCT01580670 · Phase 3 · monotherapy

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hemay007's landscape · infliximab's landscape